Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Roundtable (3)
66 Articles Available
3
3
Can't find what you're looking for? Try our
advanced search
.
Roundtable
Q: Has Downstream Processing Technology Caught up with the Significantly Higher Titers Coming Out of the Current Upstream Process? If No, What Issues Remain?
PAP-Q2-17-RT-004
Roundtable
Q: What is the Most Significant Recent Advancement in Downstream Bioprocessing Technology? Why is it so Important?
PAP-Q2-17-RT-002
Q: How is the Need to Provide Local Drug-Product Supply in Multiple Regions Around the World Impacting Pharmaceutical Manufacturing Facility and Equipment Design?
PAP-Q1-17-RT-002
Q: What Do CROs/CDMOs Need to Do to Ensure That They Provide Effective Global Support but with Locally Oriented Services?
PAP-Q1-17-RT-001
Q: What are the Greatest Challenges Drug Manufacturers Face When Working to Meet the New Requirements for Excipient Supply Chain Security?
PAP-Q1-17-RT-006
Q: What Challenges are Associated with Implementing Cloud Computing within CROs/CDMOs?
PAP-Q1-17-RT-004
Q: What Impact Do You Think the Move to Cloud Computing Will Have on the Ability of Contract Service Organizations to Better Meet the Needs of Their Customers?
PAP-Q1-17-RT-003
Q: What New Technology Introduced Within the Last Year Have You Found to Have the Most Impact on Your Business?
PAP-Q04-16-RT-001
Q: What is Your Perception of the State of Serialization in Your Sector of the Pharma Industry?
PAP-Q04-16-RT-003
Q: What Are You Doing to Become a Premier Outsourcing Partner in the Context of FDA’s Recent Shift to a Focus on Quality Culture Rather than Just Metrics?
PAP-Q04-16-RT-002
The FDA Recently Validated a Continuous Manufacturing Pharma Process Line—What Do You Think This Means for the Future?
PAP-Q03-16-RT-001
Q: With Respect to Supplier-Partner Relationships, What is Your Preferred Collaboration Model?
PAP-Q03-16-RT-003
Q: What Have You Found to be the Greatest Benefit from Close Collaboration Partnership Models?
PAP-Q03-16-RT-005
In Close Supplier-Partner Relationships, What Pitfalls Do You Try to Avoid? How Close is Too Close?
PAP-Q03-16-RT-004
Q: When it Comes to Processing, What Technology Will Have the Most Impact on Pharma Processing Over the Next 10 Years?
PAP-Q03-16-RT-002
Bioavailability: What Are Your Thoughts On Enhancing Bioavailability With Novel Technologies?
PAP-Q02-16-RT-001
Antibody-Drug Conjugate: Do We Understand The Capital Investment In Our Staff?
PAP-Q02-16-RT-003
Biosimilars: Are We on the Edge of a New Era of Biologics?
PAP-Q02-16-RT-002
«
3
3